Liquid Biopsy in High-grade Gliomas and Meningiomas

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-01

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The general objective of this project is to evaluate the value of cell-free DNA circulating in plasma as a marker of tumor evolution in patients with high-grade gliomas and meningiomas.

To this end, we propose to longitudinally collect four samples of plasma at the following time points:

* T0: before surgery;
* T1: one month after surgery;
* T2: one month after the end of radiotherapy;
* T3 at the time of radiological progression.

The goal is to evaluate whether changes in plasma concentration of circulating cell-free DNA can help predict progression-free survival, overall survival, and response to therapies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Analysis of Circulating DNA in Blood Samples of Glioma-affected Patients

NCT05964153

Glioma Circulating Tumor Cell

UNKNOWN NA

Validation Study of a Serum-miRNA Signature in Glioma Patients.

NCT06178692

Biomarker

ACTIVE_NOT_RECRUITING

Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients - MIND

NCT07282470

Meningioma Meningioma of Brain

RECRUITING

Circulating Tumor DNA Collection From Patients With High Grade Gliomas

NCT05925218

High Grade Glioma

RECRUITING

Monitoring of Patients With Diffuse Gliomas Using Circulating miRNAs

NCT06203496

Glioma, Malignant

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

High Grade Glioma High Grade Meningioma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Finding, on an MRI scan of the brain with gadolinium, of a brain lesion compatible with a primary brain tumor, intra- or extra-axial, suspected for a high-grade glioma or a high-grade meningioma, manifested with new onset neurological symptoms
* Clinical indication to perform a biopsy or surgical resection of the lesion
* Karnofsky Performance Status (KPS) ≥ 60
* Signature of informed consent

Exclusion Criteria

* Absolute contraindications to magnetic resonance imaging or to the administration of gadolinium (e.g. patients with pacemakers or other non-magneto-compatible devices)
* Known positivity for HIV, HCV or HBV
* There are clinical, biological or instrumental data suggesting that the brain lesion is non-neoplastic in nature (e.g., abscess, vascular malformation, inflammatory disease of the Central Nervous System)
* Women who are pregnant or breastfeeding

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No